Company Profile

Poniard Pharmaceuticals Inc (AKA: NeoRx Corporation)
Profile last edited on: 12/2/2023      CAGE: -----      UEI: ----------

Business Identifier: Cancer therapeutics: radiotherapy and trichothecene technologies
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 Elliott Avenue West Suite 500
Seattle, WA 98119
   (206) 281-7001
Location: Multiple
Congr. District: 07
County: King

Public Profile

In 2006, having gone public in 1988 only a year of two after becoming SBIR involved but graduating out of the program in 2004, NeoRx Corporation changed name to Poniard Pharmaceuticals, Inc (NASDAQ:PARD). The firm raised major amounts of capital both before and after going public and had working relations of ocnsequence with almost every corporate and academic entity in the space. An effort was made unsuccessfuly to achieve a reverse merger with Allozyne in 2011. For a while trading as Poniard Pharmaceuticals Inc (PARD:OTC Pink, in 2014, Verastem Inc. (cancer stem cell-targeting therapies) licensed all rights to focal adhesion kinase (FAK) inhibitors for cancer originally acquired from the Scripps Research Institute. Subsequently, the firm appears simply to have closed its doors.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 2 NIH $850,759
Project Title: Melanoma Radiotherapy- Peptide Targeted Alpha-Radiation
2002 2 NIH $1,187,550
Project Title: Pretargeted Rit To Treat Non-Hodgkin's Lymphoma
2001 1 NIH $108,679
Project Title: Gemcitabine Potentiation of Pretarget RIT
2001 2 NIH $1,191,714
Project Title: Alpha Radiotherapy Via Pretargeted Lead 212
2000 1 NIH $99,996
Project Title: Bispecific Antibody Pretargeting For Cancer Therapy

Key People / Management

  Paul G Abrams -- President

  Donald B Axworthy

  Alan R Fritzberg

  Gowsala Pavanasaivam

  Thomas P Quinn

  John M Reno

  Robert W Schroff

  Jonathan F Tait

  Lauren M Tatalick

  Scott D Wilbur